☆ 4.6 Article

Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis

CANCERS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Oncology

Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis

Gauri Mishra et al.

Summary: This study investigated the clinical utility of the emerging prognostic model, Albumin-Bilirubin (ALBI) grade, in patients with hepatocellular cancer (HCC) undergoing transarterial chemoembolization (TACE). The results showed that higher pre-treatment ALBI grade was associated with poorer prognosis in these patients.

JOURNAL OF GASTROINTESTINAL CANCER (2023)

添加到收藏夹

Review Medicine, Research & Experimental

Immunotherapy for hepatocellular carcinoma

Mingzhen Zhou et al.

Summary: Hepatocellular carcinoma (HCC) is a common malignancy with late-appearing symptoms, making diagnosis and treatment challenging. Immunotherapy, including immune checkpoint inhibitors, liver cancer vaccines, and cellular therapies, has emerged as a new hope for HCC treatment by regulating the immune system to target liver cancer cells.

CLINICAL AND EXPERIMENTAL MEDICINE (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function

Giuseppe Cabibbo et al.

Summary: The number of effective systemic therapies for advanced hepatocellular carcinoma is increasing rapidly, with immunotherapy leading to improved survival outcomes. However, many patients still receive tyrosine kinase inhibitors due to contraindications to immune checkpoint inhibitors. Maintaining optimal liver function and managing hepatic decompensation are crucial in defining the treatment sequence.

DIGESTIVE AND LIVER DISEASE (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

Risk of hepatocellular carcinoma after hepatitis C virus cure

Maria Alejandra Luna-Cuadros et al.

Summary: Hepatitis C virus (HCV) is a major cause of hepatocellular carcinoma (HCC) and the introduction of direct-acting antivirals has revolutionized HCV therapy. Successful treatment greatly reduces the risk of HCC, but certain patients, especially those with cirrhosis, remain at risk even after achieving sustained virologic response (SVR). Noninvasive modalities and various fibrosis scores may be used to monitor hepatic fibrosis and predict the risk of HCC in patients with SVR, but further validation and standardization are needed before implementing them in routine clinical care.

WORLD JOURNAL OF GASTROENTEROLOGY (2022)

添加到收藏夹

Review Oncology

Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review

Manon Falette Puisieux et al.

Summary: Hepatocellular carcinoma (HCC) is a major health problem and the fourth leading cause of cancer-related mortality worldwide. The prognosis for advanced HCC is poor, and the selection of optimal treatment remains a challenge. However, recent studies have shown that the combination of atezolizumab and bevacizumab can significantly improve survival and is recommended as the first-line treatment for advanced HCC. Other treatments, such as regorafenib and cabozantinib, can be considered for disease progression. Transarterial chemoembolization is also an alternative treatment for patients with intermediate-stage HCC. The accurate estimation of liver function is crucial for therapeutic management.

CANCERS (2022)

添加到收藏夹

Review Oncology

Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities

Carmelo Laface et al.

Summary: Hepatocellular carcinoma is the most common primary liver cancer with poor prognosis. New molecular targeted therapies have shown promising results in recent years. However, research into new treatments is still necessary.

CANCERS (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma

Soojin Kim et al.

Summary: Patients with unresectable hepatocellular carcinoma in Korea showed longer progression-free survival when treated with lenvatinib compared to sorafenib, and there were no significant differences in overall survival between the two treatments, suggesting that lenvatinib is non-inferior to sorafenib.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

The changing scenario of hepatocellular carcinoma in Italy: an update

Francesca Garuti et al.

Summary: In Italy, over the last 15 years, there has been a gradual increase in age of HCC patients, a rise in non-viral cases, and improvements in clinical management. Different treatment methods have shown positive outcomes, leading to an overall increase in survival rates.

LIVER INTERNATIONAL (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study

Margherita Rimini et al.

Summary: Lenvatinib showed better performance compared to Sorafenib in a real-world setting, with more research needed to validate predictor factors for Lenvatinib response over Sorafenib.

HEPATOLOGY RESEARCH (2021)

添加到收藏夹

Article Oncology

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy

Valentina Burgio et al.

Summary: This multicentric study in Italy demonstrated that patients with unresectable HCC treated with lenvatinib had lower risk of death, longer progression-free survival, higher response rate compared to those treated with sorafenib. Lenvatinib was also associated with different safety profile than sorafenib in Italian patients.

CANCER MANAGEMENT AND RESEARCH (2021)

添加到收藏夹

Review Oncology

Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib

Marie Decraecker et al.

Summary: The use of atezolizumab and bevacizumab in advanced hepatocellular carcinomas has changed the therapeutic approach, emphasizing the need to redefine the role of tyrosine kinase inhibitors, particularly lenvatinib. This review aims to explore potential indications for lenvatinib treatment in different clinical scenarios and highlights the evolving landscape of systemic treatment options in hepatocellular carcinoma.

CANCERS (2021)

添加到收藏夹

Article Oncology

Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis

Yuan-Hung Kuo et al.

Summary: In clinical practice, lenvatinib showed superior progression-free survival, disease control rates, and equivalent treatment-related adverse events compared to sorafenib for patients with unresectable HCC, while also reducing the risk of disease progression. However, lack of approved post-lenvatinib systemic therapies remains a significant issue in the real world.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib

M. Rimini et al.

Summary: The study showed that NASH is an independent prognostic factor in advanced HCC patients treated with lenvatinib, suggesting its potential role in patient selection for tyrosine kinase treatment. If validated, this finding could provide new insights to enhance the management of these patients.

ESMO OPEN (2021)

添加到收藏夹

Article Multidisciplinary Sciences

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister et al.

Summary: The study investigated the impact of NASH on immunotherapy response in HCC patients and found that NASH-HCC may be less responsive to immunotherapy. Aberrant T cell activation caused by NASH-related tissue damage led to impaired immune surveillance in HCC patients.

NATURE (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma

Tetsu Tomonari et al.

Summary: The study found that lenvatinib is more effective in treating nonviral hepatocellular carcinoma (HCC) compared to viral HCC. The nonviral group showed higher objective response rate, longer progression-free survival, and significantly longer overall survival than the viral group.

JGH OPEN (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib

Toshifumi Tada et al.

Summary: The study showed that mALBI grade was a better predictor of survival than Child-Pugh classification in patients with unresectable HCC who received lenvatinib therapy. This was particularly evident in patients with a Child-Pugh score of 5. Time-dependent receiver operating characteristic analysis also indicated that the ALBI score was a superior predictor of survival compared to the Child-Pugh score.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study

Atsushi Hiraoka et al.

Summary: The study found that lenvatinib was more effective in improving progression-free survival in NAFLD/NASH-related u-HCC patients compared to viral/alcohol-related patients, with no significant difference in overall survival. Elevated ALT, modified ALBI grade 2b, elevated AFP, and NAFLD/NASH etiology were identified as significant prognostic factors for PFS.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Oncology

Lenvatinib for Hepatocellular Carcinoma Patients with Nonviral Infection Who Were Unlikely to Respond to Immunotherapy: A Retrospective, Comparative Study

Takeshi Hatanaka et al.

Summary: The study investigated the efficacy and safety of lenvatinib in patients with nonviral infection and found no significant difference in response compared to patients with viral infection. Treatment strategies based on the etiology of liver disease may lead to good clinical outcomes.

ONCOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister et al.

Summary: The text discusses the impact of NASH on the development of HCC and the effect of immunotherapy, revealing the accumulation of exhausted and unconventionally activated CD8(+)PD1(+) T cells in NASH-affected livers. In preclinical models of NASH-induced HCC, anti-PD1 treatment led to an increase in HCC, with CD8(+) T cells contributing to this increase.

NATURE (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

mRECIST for HCC: Performance and novel refinements

Josep M. Llovet et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹

Review Oncology

Efficacy of Regorafenib in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis

Antonio Facciorusso et al.

CANCERS (2020)

添加到收藏夹

Review Immunology

Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma

Mohamed A. Abd El Aziz et al.

VACCINES (2020)

添加到收藏夹

Review Substance Abuse

Alcohol use disorders and the risk of progression of liver disease in people with hepatitis C virus infection - a systematic review

Laura Llamosas-Falcon et al.

SUBSTANCE ABUSE TREATMENT PREVENTION AND POLICY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Primary Treatment with Molecular-Targeted Agents for Hepatocellular Carcinoma: A Propensity Score-matching Analysis

Masahito Nakano et al.

HEPATOLOGY COMMUNICATIONS (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis

Atsushi Hiraoka et al.

HEPATOLOGY RESEARCH (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting

Shuntaro Obi et al.

HEPATOLOGY INTERNATIONAL (2019)

添加到收藏夹

Article Oncology

Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis

Atsushi Hiraoka et al.

CANCER MEDICINE (2019)

添加到收藏夹

Article Public, Environmental & Occupational Health

Marginal Time-Dependent Causal Effects in Mediation Analysis With Survival Data

Francesca Fasanelli et al.

AMERICAN JOURNAL OF EPIDEMIOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

AASLD guidelines for the treatment of hepatocellular carcinoma

Julie K. Heimbach et al.

HEPATOLOGY (2018)

添加到收藏夹

Article Oncology

Hepatocellular Carcinoma Is Diagnosed at a Later Stage in Alcoholic Patients: Results of a Prospective, Nationwide Study

Charlotte E. Costentin et al.

CANCER (2018)

添加到收藏夹

Article Medicine, General & Internal

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo et al.

LANCET (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Impact of smoking habit on surgical outcomes in non-B non-C patients with curative resection for hepatocellular carcinoma

Keita Kai et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2017)

添加到收藏夹

Review Oncology

Viral hepatitis and hepatocellular carcinoma: etiology and management

Philippe J. Zamor et al.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma

Francesca Romana Ponziani et al.

LIVER INTERNATIONAL (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Lymphocyte-to-monocyte ratio predicts survival after radiofrequency ablation for colorectal liver metastases

Antonio Facciorusso et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2016)

添加到收藏夹

Review Gastroenterology & Hepatology

Trends in the management and burden of alcoholic liver disease

Philippe Mathurin et al.

JOURNAL OF HEPATOLOGY (2015)

添加到收藏夹

Review Medicine, General & Internal

CURRENT CONCEPTS Hepatocellular Carcinoma

Hashem B. El-Serag

NEW ENGLAND JOURNAL OF MEDICINE (2011)

添加到收藏夹

Article Medicine, General & Internal

Sorafenib in advanced hepatocellular carcinoma

Josep M. Llovet et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.